Companies /Healthcare

Becton Dickinson & Company

NYSE: BDX Medical Instruments & Supplies
$216.15
▲ $0.73 (+0.34%) today
Markets open · 2:33pm ET

24/7 Wall St. View

BDX at a Glance

Valuation
Market cap
$58.7B
P/E ratio
42.6
Profitability
Revenue (TTM)
$19.5B
Profit margin
5.9%
EPS (TTM)
$5.06
Price
52-week range
$139 – $220
24/7 target
$264.50
Street target
$226.14
Earnings
Next report
Feb 8, 2027

Headquartered in Franklin Lakes, NJ Fiscal year ends September NYSE: BDX bd.com

About Becton Dickinson

Becton, Dickinson and Company (BD) is a pure-play medical technology company with more than 60,000 employees that delivers billions of products annually to healthcare providers worldwide. After the February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation, BD ('New BD') operates four segments:
- Medical Essentials: Medication Delivery Solutions and Specimen Management.
- Connected Care: Medication Management Solutions, including pharmacy automation such as the BD Vmax robot, and Advanced Patient Monitoring.
- BioPharma Systems: drug delivery systems for pharmaceutical companies.
- Interventional: Peripheral Intervention, Urology and Critical Care, and Surgery, including vascular stents and tissue regeneration products such as Phasix Mesh and GalaFLEX scaffolds.

About 60% of revenue comes from the United States. BD is executing its 'Excellence Unleashed' strategy and has committed to a multi-year U.S. manufacturing investment program in partnership with the U.S. Government. Updated

Latest Activity

EWEdwards Lifesciences
52-week high
$107.19
+1.30%vs prior 52-week high · Nov 12, 2026

A second straight record close for the valve maker at $107.19, 1.3% above Thursday's peak. Medtronic rose 1.88% and Abbott 1.22% the same day, so the medtech bid was broad.

Related stockstoday
  • MDTMedtronic plc.Competitor+1.9%
    Dec 31, 2025 · SEC 10-K
  • ABTAbbott LaboratoriesCompetitor+1.2%
    Dec 31, 2025 · SEC 10-K
  • BDXBecton DickinsonPartner+1.1%
    Sep 30, 2025 · SEC 10-K

Moves: Nov 13, 2026 · Alpha Vantage daily close

BDXBecton Dickinson
Q4 2026
EPS
$4.15
est $4.07+2.0%
Revenue
$5.27B
est $5.11B+3.1%

The first full quarter of the slimmed down MedTech company beat on both lines, and management guided fiscal 2027 adjusted EPS to $13.10 to $13.30 against $12.70 last year. Free cash flow jumped 42.5%, the tell that the Life Sciences spin is paying off.

Quarterly EPS — reported vs estimate
BDXBecton Dickinson
After-hours
$209.08
+4.38%open $200.30

A 4.38% day adds roughly $2.4 billion to a $57 billion medtech name that rarely moves like this. Whether the $209.08 level holds into the next session is the thing to watch.

BDXBecton Dickinson
Regular session
$208.57
+4.13%open $200.30

A 4.13% move to $208.57 adds roughly $2.3 billion to a $56.8 billion medtech name that rarely travels this far in a single session. Worth seeing whether it holds into the close.

BDXBecton Dickinson
New 52-week high$193.76+1.5% vs prior high · 2026-08-21

Becton Dickinson closed at $193.76, a fresh 52-week high and 1.51% above the prior peak set on August 21. The $52.8 billion medtech name spent most of the spring in the $140s.

BDX Coverage

2:38pm ET
Investing

3 Undervalued Dividend Kings to Buy on the Dip Right Now

Dividend Kings are stocks that’ve had their dividend payouts raised for 50 consecutive years or more, such as Target (NYSE:TGT | TGT Price Prediction), Becton Dickinson (NYSE:BDX), and Hormel Foods (NYSE:HRL). That…

Omor Ibne Ehsan

Frequently Asked Questions

What does Becton Dickinson do?

Becton, Dickinson and Company (BD) is a pure-play medical technology company with more than 60,000 employees that delivers billions of products annually to healthcare providers worldwide.

What is the BDX stock price target?

24/7 Wall St.'s 12-month price target for BDX is $264.50, rated Buy. The Wall Street consensus target is $226.14. BDX price prediction →